SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K
                                 CURRENT REPORT

                         PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

       Date of Report (Date of earliest event reported): November 7, 2002


                           OraSure Technologies, Inc.
                           --------------------------
                 (Exact name of issuer as specified in charter)


           DELAWARE                   1-10492                  36-4370966
      (State or Other              (Commission              (I.R.S. Employer
         Jurisdiction                  file                  Identification
     of Incorporation or              number)                   Number)
         Organization)


                               150 Webster Street
                          Bethlehem, Pennsylvania 18015
                    (Address of principal executive offices)

                                 (610) 882-1820
              (Registrant's telephone number, including area code)



Item 5 - Other Events.

OraSure Technologies, Inc. (the "Company") issued a press release on November 7,
2002, announcing the receipt of U.S. Food and Drug Administration ("FDA")
approval of the Company's OraQuick(R) Rapid HIV-1 Antibody Test for the
detection of HIV-1 antibodies in finger-stick whole blood samples. A copy of the
press release is attached to this Report as Exhibit 99 and is incorporated
herein by reference.



Signatures

     Pursuant to the requirements of the Securities and Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.

                                             OraSure Technologies, Inc.


Date: November 7, 2002                       By: /s/ Jack E. Jerrett
                                                 -------------------------------
                                                 Jack E. Jerrett
                                                 Vice President, General Counsel
                                                 and Secretary



                                  EXHIBIT INDEX

Exhibit

  99           Press Release issued November 7, 2002 by OraSure Technologies
               announcing the receipt of U.S. Food and Drug Administration
               ("FDA") approval of the Company's OraQuick(R) Rapid HIV-1
               Antibody Test for the detection of HIV-1 antibodies in
               finger-stick whole blood samples.





                                                                      Exhibit 99

[LOGO] OraSure Technologies, Inc.
       diagnostic solutions for the new millennium

Company Contacts:

Financial/Investors
Ronald H. Spair
Chief Financial Officer
610-882-1820
Investorinfo@orasure.com
www.orasure.com

Media
William E. Bruckner
Vice President, Strategic Marketing
610-882-1820

                        ORASURE RECEIVES FDA APPROVAL FOR
                          ORAQUICK(R) RAPID HIV-1 TEST

   - Investor Conference Call and Press Conference at 2:15 P.M. Eastern Time -

BETHLEHEM, PA - November 7, 2002 - OraSure Technologies, Inc. (Nasdaq NM:OSUR),
the market leader in oral fluid diagnostics, announced today that it has
received approval from the U.S. Food and Drug Administration ("FDA") for its
OraQuick(R) Rapid HIV-1 Antibody Test. Pursuant to this approval, the Company
can manufacture and market the OraQuick(R) test in the United States for the
detection of HIV-1 antibodies in finger-stick whole blood samples.

OraQuick(R) is the first FDA-approved rapid, point-of-care test designed to
detect antibodies to HIV-1 within approximately 20 minutes. The FDA approval is
based on clinical data submitted by OraSure indicating that the OraQuick(R) test
had sensitivity of 99.6% and specificity of 100% in the clinical studies
performed with finger-stick whole blood specimens. Sensitivity is a measure of
the accuracy for detecting positive specimens, and specificity is a measure of
the accuracy for identifying negative specimens.

"We are very pleased to be the first company in the United States to receive FDA
approval for a rapid, point-of-care HIV-1 test," said Mike Gausling, OraSure's
Chief Executive Officer. "OraQuick(R) represents an important advance for rapid
diagnostic testing, and an important milestone for the Company as we continue to
build our leadership position in the point-of-care market."

On June 17, 2002, OraSure announced that it had entered into an agreement with
Abbott Laboratories for the co-exclusive distribution of the OraQuick(R) test in
the United States. Abbott Laboratories is the market leader for the distribution
of infectious disease testing



products, and is expected to focus its efforts on selling the OraQuick(R) test
to hospitals and physicians' office laboratories. Sales from OraSure to Abbott
are expected to begin in the next 30 to 60 days.

"OraQuick(R) is an important tool to assist in the rapid detection of HIV, and
our collaboration with OraSure will ensure that this innovative technology is
made widely available to the health care professionals and patients who need
it," said Ed Michael, vice president, immunoassay and clinical chemistry, Abbott
Laboratories.

With this FDA approval, OraQuick(R) will be available for sale to the nearly
40,000 qualified locations in the United States certified under CLIA (Clinical
Laboratory Improvement Act of 1988) to perform moderately complex diagnostic
tests. An estimated 17 million HIV tests are conducted annually in the United
States at these locations.

"We are extremely pleased with the accuracy of the OraQuick(R) test", added R.
Sam Niedbala, Ph.D., OraSure's Chief Science Officer. "Development of this
product and receipt of FDA approval are the culmination of extensive efforts by
our research and development, manufacturing, regulatory and quality groups."

Conference Call/Audio Webcast

OraSure Technologies will host a conference call with analysts and an audio
webcast to discuss the OraQuick(R) FDA approval beginning at 2:15 p.m. Eastern
Time (11:15 a.m. Pacific Time) today. On the call will be Mike Gausling, Chief
Executive Officer, Ronald H. Spair, Chief Financial Officer, Mike Formica,
Senior Vice President, Operations, and Eve Damiano, Vice President, Regulatory
Affairs.

In order to listen to the conference call, please either dial 888-742-2024
(Domestic) or 706-643-0033 (International) or go to OraSure Technologies' web
site, www.orasure.com, and click on the Investor Info link at the top of the
page, at least ten minutes prior to the start of the call, to register and
download and install any necessary audio software. A replay of the call will be
archived on OraSure Technologies' web site shortly after the call has ended and
will be available for seven days. A replay of the call can also be accessed
until November 12, 2002, by dialing 800-642-1687 (Domestic) or 706-645-9291
(International) and entering the Conference ID #6610260.

The webcast will also be distributed over the CCBN (Corporate Communications
Broadcast Network) Investor Distribution Network. Institutional investors can
access the call via CCBN's password protected event management site,
StreetEvents (www.streetevents.com).

About OraSure Technologies

OraSure Technologies develops, manufactures and markets oral fluid specimen
collection devices and tests and other diagnostic products using its proprietary
technologies, including immunoassays and other in vitro diagnostic tests and
other medical devices. These products are sold in the United States and certain
foreign countries to government



agencies, clinical laboratories, physicians' offices, hospitals, commercial and
industrial entities, and various distributors.

OraSure Technologies is the leading supplier of oral-fluid collection devices
and assays to the life insurance industry and public health markets for the
detection of antibodies to HIV-1. In addition, the Company supplies oral-fluid
testing solutions for drugs of abuse testing. For more information on the
Company, please go to www.orasure.com.

About Abbott Laboratories

Abbott is a leader in HIV testing, beginning with the licensure of the first HIV
test in the United States in 1985. Since then, Abbott has continually improved
the diagnostic effectiveness of its tests, targeting sensitivity to detect HIV
infections earlier and developing advanced technology to automate HIV testing
for patient diagnosis, managing therapy and screening donated blood. Abbott also
has developed important HIV therapeutics including Norvir, Abbott's first
protease inhibitor, and Kaletra, an advanced-generation protease inhibitor, for
the treatment of HIV/AIDS.

Abbott is a global, broad-based health care company devoted to the discovery,
development, manufacture and marketing of pharmaceuticals, nutritionals, and
medical products, including devices and diagnostics. The company employs
approximately 70,000 people and markets its products in more than 130 countries.
For more information on Abbott, please go to www.abbott.com.

Important Information

This press release contains certain forward-looking statements, including with
respect to sales, markets and products. Actual results could be significantly
different. Factors that could affect results include the ability to market
products; impact of competitors, competing products and technology changes;
ability to develop, commercialize and market new products; market acceptance of
oral fluid testing or other products; ability to fund research and development
and other projects and operations; ability to obtain and timing of obtaining
necessary regulatory approvals; ability to develop product distribution
channels; uncertainty relating to patent protection and potential patent
infringement claims; ability to enter into international manufacturing
agreements; obstacles to international marketing and manufacturing of products;
ability to sell products internationally; loss or impairment of sources of
capital; exposure to product liability and other types of litigation; changes in
international, federal or state laws and regulations; changes in relationships
with strategic partners and reliance on strategic partners for the performance
of critical activities under collaborative arrangements; changes in accounting
practices or interpretation of accounting requirements; customer inventory
practices and consolidations; equipment failures and ability to obtain needed
raw materials and components; the impact of terrorism and civil unrest; and
general business, political and economic conditions. These and other factors are
discussed more fully in the Securities and Exchange Commission filings of
OraSure Technologies, including its registration statements, its Annual Report
on Form 10-K for the year ended December 31, 2001, and its most recent Quarterly
Report on Form 10-Q. Although forward-looking statements help to provide
complete information about future prospects, readers should keep in mind that
forward-looking statements may not be reliable. The forward-looking statements
are made



as of the date of this press release and OraSure Technologies undertakes no duty
to update these statements.

                                      # # #